Spasticity - Pipeline Insight, 2025

This “Spasticity - Pipeline Insight, 2025,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Spasticity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Spasticity Understanding

Spasticity: Overview

Spasticity is a condition in which there is an abnormal increase in muscle tone or muscle stiffness, which might interfere with movement and speech or be associated with discomfort or pain. Spasticity is usually caused by damage to nerve pathways within the brain or spinal cord that control muscle movement. It may be related to spinal cord injury, multiple sclerosis, cerebral palsy, stroke, brain or head trauma, amyotrophic lateral sclerosis, hereditary spastic paraplegias, and metabolic diseases such as adrenoleukodystrophy, phenylketonuria, and Krabbe disease. Spasticity is generally caused by damage or disruption to the brain and spinal cord area responsible for controlling muscle and stretch reflexes. These disruptions can be due to an imbalance in the inhibitory and excitatory signals sent to the muscles, causing them to lock in place. Spasticity can harm growing children as it affects muscles and joints.

'Spasticity - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spasticity pipeline landscape is provided which includes the disease overview and Spasticity treatment guidelines. The assessment part of the report embraces, in depth Spasticity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence in Spasticity R&D. The therapies under development are focused on novel approaches to treat/improve in Spasticity.

This segment of the Spasticity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Spasticity Emerging Drugs

HU-014: Huons

HU-014 (Liztox) is a newly developed Botulinum toxin A. Botulinum toxin dose is measured in units (U) based on the median lethal dose (LD50) of the neurotoxin. HU-014 is a highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum, the bacterium responsible for botulism. The botulinum toxin weakens or paralyzes skeletal muscle by inhibiting neurotransmission between peripheral nerve endings and muscle fibers. The effects of botulinum toxin are transient; muscular function typically returns to baseline within a few months.

Myobloc: Supernus Pharmaceuticals

Myobloc (rimabotulinumtoxinB) injection is the first and only approved botulinum toxin Type B injectable indicated for the treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia in adults and the treatment of chronic sialorrhea in adults. MYOBLOC blocks cholinergic transmission at the neuromuscular and salivary neuroglandular junction by inhibiting the release of acetylcholine from peripheral cholinergic-nerved terminals. Currently it is being evaluated in Phase II/III clinical trials to treat upper and lower limb spasticity.

Spasticity: Therapeutic Assessment

This segment of the report provides insights about the different Spasticity drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Spasticity

There are approx. 20+ key companies which are developing the therapies for Spasticity. The companies which have their Spasticity drug candidates in the most advanced stage, i.e. Phase III include, Huons.

Phases

The report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Spasticity: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spasticity therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spasticity drugs.

Spasticity Report Insights

• Spasticity Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Spasticity Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Spasticity drugs?
• How many Spasticity drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spasticity?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Spasticity?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Spasticity and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• RVL Pharmaceuticals
• Huons
• Bionorica SE
• Supernus Pharmaceuticals
• Saol Therapeutics
• Revance Therapeutics
• Flex Pharma
• Canbex Therapeutics
• Ipsen
• Lundbeck A/S
• CKD Bio Corporation
• Sentynl Therapeutics
• Shionogi
• Lexicon Pharmaceuticals
• Incannex
• Delpor
• Ethicann Pharmaceuticals

Key Products

• Arbaclofen extended release
• HU-014
• BX-1
• Myobloc
• SL-1002
• DAXI
• FLX 787
• VSN-16R
• IPN10200
• IPN59011
• Lu AG06466
• CKDB-501A
• STI-103
• S-109802
• LX9211
• Medchew Rx
• DLP-208

This product will be delivered within 1-3 business days.